# China Biotech

> China Biotech is a VC fund in Beijing backing Medical, Health Care and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 2
- Last investment: Dec 2021
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.cnbg.com.cn/

China Biotech is a biomedical product developer, mainly engaged in comprehensive research and product production of vaccines, blood products, animal health and medical beauty. It has successively developed and produced smallpox, cholera, typhoid, rabies vaccines and diphtheria antitoxin products, and successfully isolated them Penicillin strain.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Clinical Trials | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sumgen Biotech | Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CARTantibodies. . |  |  | Dec 07, 2021 |  |
| Sumgen Biotech | Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CARTantibodies. . |  | Series B | Dec 07, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 2 deals together
- Baopu Asset Management — VC Fund, 2 deals together
- Hankang Capital — VC Fund, 2 deals together
- [JC Capital](https://shizune.co/investors/profile/jc-capital) — VC Fund, 2 deals together
- [Sinopharm Capital](https://shizune.co/investors/profile/sinopharm-capital) — VC Fund, 2 deals together
- [ZSVC](https://shizune.co/investors/profile/zsvc) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does China Biotech invest in?

China Biotech invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did China Biotech last invest?

The most recent investment recorded for China Biotech closed in Dec 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co